Fortress Biotech to Participate in October 2024 Investor Conferences
September 26, 2024 08:30 ET
|
Fortress Biotech, Inc.
MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term...
Orphan Drugs Market Size & Share to Surpass USD 424.0 billion by 2034, Rising a CAGR 6.9% | Analysis by Transparency Market Research, Inc.
September 26, 2024 07:14 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The orphan drugs market (희귀의약품 시장) was worth US$ 195.0 billion in 2023. The market is...
Global Bispecific Antibodies Clinical Trials Market Size FDA Approved Bispecific Antibodies Insight
September 26, 2024 06:52 ET
|
KuicK Research
Delhi, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Market, Drugs Sales, Patent, Price and Clinical Trials Insight 2029 Report Highlights: Bispecific Antibodies Development...
Amoxicillin Market Research Report 2024: Combination Therapies and Immunotherapy Trends Shaping Future Landscape - Global Long-term Forecast to 2028 and 2033
September 26, 2024 04:02 ET
|
Research and Markets
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Amoxicillin Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The amoxicillin market size has grown steadily in...
Global healthcare AI innovator Qure.ai completes $65 million Series D funding round led by Lightspeed and 360One Asset
September 25, 2024 12:00 ET
|
Qure.ai Technologies Limited
Global healthcare AI innovator Qure.ai completes $65 million Series D funding round led by Lightspeed and 360One Asset
Abiologics Strengthens Leadership Team with Appointment of Maria-Chiara Magnone as Chief Scientific Officer
September 25, 2024 07:00 ET
|
Abiologics
CAMBRIDGE, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Abiologics, a company reimagining biologics with the creation of a new class of supranatural and programmable medicines called Synteins™, today...
Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
September 24, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Renal Cancer Clinical Trial Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight ...
Transgene prévoit d’importants résultats cliniques d’ici fin 2024 et confirme sa visibilité financière jusqu’au 4ème trimestre 2025
September 24, 2024 11:45 ET
|
Transgene S.A.
Résultats financiers du 1er semestre 2024 et point sur l’activité Produit phare TG4050 (vaccin thérapeutique individualisé) : - Premiers signes de bénéfice clinique dans le cancer...
Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025
September 24, 2024 11:45 ET
|
Transgene S.A.
2024 Half-Year Results and Business Update Lead program TG4050 (individualized immunotherapy): – First signs of clinical benefit in adjuvant head and neck cancer reported at AACR 2024,...
Cancer Supportive Care Product Market is Set to Surge at 6.9% CAGR, to Reach US$ 68.93 Billion by 2034 | Fact.MR
September 24, 2024 06:00 ET
|
FACT.MR
Rockville, MD, Sept. 24, 2024 (GLOBE NEWSWIRE) -- In its new study, Fact.MR states that the global cancer supportive care product market is estimated to reach a value of US$ 35.47 billion in 2024...